Increased expression of Siglec-1 on peripheral blood monocytes and its role in mononuclear cell reactivity to autoantigen in rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 53, Issue 2, 2014, Pages 250-259

  Xiong, Yi Song ^a   Cheng, Yue ^a   Lin, Qiu Shui ^b   Wu, Ai Lin ^a   Yu, Juan ^c   Li, Chang ^c   Sun, Yi ^d   Zhong, Ren Qian ^c   Wu, Li Juan ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

^b No 411 Hospital of PLA   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Activation; Biological markers; Disease activity score; Proliferation; RA; Siglec 1

Indexed keywords

AUTOANTIGEN; C REACTIVE PROTEIN; COLLAGEN TYPE 2; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; IMMUNOGLOBULIN M; MESSENGER RNA; MITOGENIC AGENT; SIALOADHESIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALE; MIDDLE AGED; MONOCYTE; MONONUCLEAR CELL; OSTEOARTHRITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS;

ACTIVATION; BIOLOGICAL MARKERS; DISEASE ACTIVITY SCORE; PROLIFERATION; RA; SIGLEC-1;

ADULT; ARTHRITIS, RHEUMATOID; AUTOANTIGENS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE II; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN M; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MONOCYTES; OSTEOARTHRITIS; RNA, MESSENGER; SIALIC ACID BINDING IG-LIKE LECTIN 1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892550193     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket342     Document Type: Article

References (35)

1. Cooles FA, Isaacs JD. Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol 2011;23:233-40.
2. Scheinecker C, Smolen JS. Rheumatoid arthritis in 2010: from the gut to the joint. Nat Rev Rheumatol 2011;7:73-5.
3. Hoes JN, Jacobs JW, Buttgereit F et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010;6:693-702.
4. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007;7:255-66.
5. Hartnell A, Steel J, Turley H et al. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood 2001;97:288-96.
6. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
7. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
8. Xiong YS, Wu AL, Lin QS et al. Contribution of monocytes Siglec-1 in stimulating T cells proliferation and activation in atherosclerosis. Atherosclerosis 2012;224:58-65.
9. Xiong YS, Zhou YH, Rong GH et al. Siglec-1 on monocytes is a potential risk marker for monitoring disease severity in coronary artery disease. Clin Biochem 2009;42:1057-63.
10. -ΔΔCT method. Methods 2001;25:402-8.
11. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
12. Zheng ZH, Li XY, Ding J et al. Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagenreactive T cells in rheumatoid arthritis. Rheumatology 2008;47:22-30.
13. Kim HY, Kim WU, Cho ML et al. Enhanced T cell proliferative response to type II collagen and synthetic peptide CII (255-274) in patients with rheumatoid arthritis. Arthritis Rheum 1999;42:2085-93.
14. Biesen R, Demir C, Barkhudarova F et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008;58: 1136-45.
15. York MR, Nagai T, Mangini AJ et al. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 2007;56:1010-20.
16. Ikezumi Y, Suzuki T, Hayafuji S et al. The sialoadhesin (CD169) expressing a macrophage subset in human proliferative glomerulonephritis. Nephrol Dial Transplant 2005;20:2704-13.
17. Asano K, Nabeyama A, Miyake Y et al. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 2011;34: 85-95.
18. Rempel H, Calosing C, Sun B et al. Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. PLoS One 2008;3:e1967.
19. Muerkoster S, Rocha M, Crocker PR et al. Sialoadhesinpositive host macrophages play an essential role in graft-versus-leukemia reactivity in mice. Blood 1999;93: 4375-86.
20. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007;66:1008-14.
21. Lertnawapan R, Bian A, Rho YH et al. Cystatin C, renal function, and atherosclerosis in rheumatoid arthritis. J Rheumatol 2011;38:2297-300.
22. Nakken B, Szodoray P. Accelerated atherosclerosis in rheumatoid arthritis: rationale for mannose-binding lectins? J Rheumatol 2010;37:482-4.
23. Wrigley BJ, Lip GY, Shantsila E. Coronary atherosclerosis in rheumatoid arthritis: could endothelial progenitor cells be the missing link? J Rheumatol 2010;37:479-81.
24. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003;19:71-82.
25. Geissmann F, Auffray C, Palframan R et al. Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol Cell Biol 2008;86:398-408.
26. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009;27: 669-92.
27. Ancuta P, Rao R, Moses A et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003;197:1701-7.
28. van der Heijde DM, van't Hof MA, van Riel PL et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
29. van der Heijde DM, van't Hof M, van Riel PL et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
30. Vander Cruyssen B, Van Looy S, Wyns B et al. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005;7:R1063-71.
31. Yildirim K, Karatay S, Melikoglu MA et al. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci 2004;34:423-6.
32. McConkey B, Crockson RA, Crockson AP. The assessment of rheumatoid arthritis. A study based on measurements of the serum acute-phase reactants. Q J Med 1972; 41:115-25.
33. Cylwik B, Chrostek L, Gindzienska-Sieskiewicz E et al. Relationship between serum acute-phase proteins and high disease activity in patients with rheumatoid arthritis. Adv Med Sci 2010;55:80-5.
34. Sellam J, Hendel-Chavez H, Rouanet S et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011;63: 933-8.
35. Clavel C, Nogueira L, Laurent L et al. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 2008;58: 678-88.